<?xml version="1.0" encoding="ISO-8859-1"?><!DOCTYPE ichicsr>
<ichicsr lang="en">
<ichicsrmessageheader>
<messagetype>ichicsr</messagetype>
<messageformatversion>2.1</messageformatversion>
<messageformatrelease>1.0</messageformatrelease>
<messagenumb>78948</messagenumb>
<messagesenderidentifier>SAAVPROD</messagesenderidentifier>
<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
<messagedateformat>204</messagedateformat>
<messagedate>20130125151123</messagedate>
</ichicsrmessageheader>
<safetyreport>
<safetyreportversion>1</safetyreportversion>
<safetyreportid>SE-SANOFI-AVENTIS-2013SA003881</safetyreportid>
<primarysourcecountry>SE</primarysourcecountry>
<occurcountry>SE</occurcountry>
<transmissiondateformat>102</transmissiondateformat>
<transmissiondate>20130125</transmissiondate>
<reporttype>1</reporttype>
<serious>1</serious>
<seriousnessdeath>2</seriousnessdeath>
<seriousnesslifethreatening>2</seriousnesslifethreatening>
<seriousnesshospitalization>1</seriousnesshospitalization>
<seriousnessdisabling>2</seriousnessdisabling>
<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
<receivedateformat>102</receivedateformat>
<receivedate>20130116</receivedate>
<receiptdateformat>102</receiptdateformat>
<receiptdate>20130116</receiptdate>
<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
<companynumb>SE-SANOFI-AVENTIS-2013SA003881</companynumb>
<duplicate>1</duplicate>
<reportduplicate>
<duplicatesource>SWE-MPA</duplicatesource>
<duplicatenumb>1244547</duplicatenumb>
</reportduplicate>
<primarysource>
<reportergivename>PRIVACY</reportergivename>
<reportermiddlename>PRIVACY</reportermiddlename>
<reporterfamilyname>PRIVACY</reporterfamilyname>
<reporterorganization>Medical Product Agency</reporterorganization>
<reporterstreet>PRIVACY</reporterstreet>
<reportercity>PRIVACY</reportercity>
<reportercountry>SE</reportercountry>
<qualification>3</qualification>
</primarysource>
<primarysource>
<reportergivename>PRIVACY</reportergivename>
<reportermiddlename>PRIVACY</reportermiddlename>
<reporterfamilyname>PRIVACY</reporterfamilyname>
<reporterstreet>PRIVACY</reporterstreet>
<reportercity>PRIVACY</reportercity>
<reportercountry>SE</reportercountry>
<qualification>2</qualification>
</primarysource>
<sender>
<sendertype>1</sendertype>
<senderorganization>sanofi-aventis</senderorganization>
<senderdepartment>US Affiliate Pharmacovigilance</senderdepartment>
<sendergivename>Barbara</sendergivename>
<senderfamilyname>Rullo</senderfamilyname>
<senderstreetaddress>55A-435 55 Corporate Drive</senderstreetaddress>
<sendercity>Bridgewater</sendercity>
<senderstate>NJ</senderstate>
<senderpostcode>08807</senderpostcode>
<sendercountrycode>US</sendercountrycode>
<sendertel>9089816698</sendertel>
<sendertelcountrycode>1</sendertelcountrycode>
<senderfax>9089877894</senderfax>
<senderfaxcountrycode>1</senderfaxcountrycode>
<senderemailaddress>Barbara.Rullo@sanofi-aventis.com</senderemailaddress>
</sender>
<receiver>
<receivertype>2</receivertype>
<receiverorganization>ZZFDA</receiverorganization>
<receiverdepartment>Center for Drug Evaluation and Research</receiverdepartment>
<receiverstreetaddress>5600 Fishers lane</receiverstreetaddress>
<receivercity>Rockville</receivercity>
<receiverstate>MD</receiverstate>
<receiverpostcode>20857</receiverpostcode>
<receivercountrycode>US</receivercountrycode>
<receivertel>3018273237</receivertel>
<receivertelcountrycode>1</receivertelcountrycode>
<receiveremailaddress>aersesub@cder.fda.gov</receiveremailaddress>
</receiver>
<patient>
<patientinitial>PRIVACY</patientinitial>
<patientonsetage>63</patientonsetage>
<patientonsetageunit>801</patientonsetageunit>
<patientagegroup>5</patientagegroup>
<patientsex>1</patientsex>
<reaction>
<primarysourcereaction>hypocalcaemia</primarysourcereaction>
<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
<reactionmeddrallt>10020947</reactionmeddrallt>
<termhighlighted>4</termhighlighted>
<reactionstartdateformat>102</reactionstartdateformat>
<reactionstartdate>20121029</reactionstartdate>
<reactionfirsttime>73</reactionfirsttime>
<reactionfirsttimeunit>804</reactionfirsttimeunit>
<reactionlasttime>1</reactionlasttime>
<reactionlasttimeunit>803</reactionlasttimeunit>
<reactionoutcome>2</reactionoutcome>
</reaction>
<reaction>
<primarysourcereaction>paresthesia</primarysourcereaction>
<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
<reactionmeddrallt>10033987</reactionmeddrallt>
<termhighlighted>4</termhighlighted>
<reactionstartdateformat>102</reactionstartdateformat>
<reactionstartdate>20121029</reactionstartdate>
<reactionfirsttime>73</reactionfirsttime>
<reactionfirsttimeunit>804</reactionfirsttimeunit>
<reactionlasttime>1</reactionlasttime>
<reactionlasttimeunit>803</reactionlasttimeunit>
<reactionoutcome>2</reactionoutcome>
</reaction>
<reaction>
<primarysourcereaction>muscle cramps</primarysourcereaction>
<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
<reactionmeddrallt>10028295</reactionmeddrallt>
<termhighlighted>4</termhighlighted>
<reactionstartdateformat>102</reactionstartdateformat>
<reactionstartdate>20121029</reactionstartdate>
<reactionfirsttime>73</reactionfirsttime>
<reactionfirsttimeunit>804</reactionfirsttimeunit>
<reactionlasttime>1</reactionlasttime>
<reactionlasttimeunit>803</reactionlasttimeunit>
<reactionoutcome>2</reactionoutcome>
</reaction>
<test>
<testdateformat>102</testdateformat>
<testdate>20121029</testdate>
<testname>10006948</testname>
<testresult>S-CA 0.97</testresult>
<testunit>MMOL/L</testunit>
<lowtestrange>2.15</lowtestrange>
<hightestrange>2.50</hightestrange>
<moreinformation>2</moreinformation>
</test>
<drug>
<drugcharacterization>1</drugcharacterization>
<medicinalproduct>JEVTANA</medicinalproduct>
<drugbatchnumb>UNKNOWN</drugbatchnumb>
<drugauthorizationnumb>NDA 201023</drugauthorizationnumb>
<drugadministrationroute>065</drugadministrationroute>
<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
<drugindication>10060862</drugindication>
<drugstartdateformat>102</drugstartdateformat>
<drugstartdate>20120817</drugstartdate>
<drugstartperiod>73</drugstartperiod>
<drugstartperiodunit>804</drugstartperiodunit>
<druglastperiod>1</druglastperiod>
<druglastperiodunit>803</druglastperiodunit>
<drugenddateformat>102</drugenddateformat>
<drugenddate>20121022</drugenddate>
<drugtreatmentduration>67</drugtreatmentduration>
<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
<actiondrug>1</actiondrug>
<drugadditional>Form:Unknown</drugadditional>
<activesubstance>
<activesubstancename>CABAZITAXEL</activesubstancename>
</activesubstance>
</drug>
<drug>
<drugcharacterization>2</drugcharacterization>
<medicinalproduct>ZOMETA</medicinalproduct>
<activesubstance>
<activesubstancename>ZOLEDRONIC ACID</activesubstancename>
</activesubstance>
</drug>
<drug>
<drugcharacterization>2</drugcharacterization>
<medicinalproduct>OMEPRAZOLE</medicinalproduct>
<activesubstance>
<activesubstancename>OMEPRAZOLE</activesubstancename>
</activesubstance>
</drug>
<drug>
<drugcharacterization>2</drugcharacterization>
<medicinalproduct>FORLAX</medicinalproduct>
<activesubstance>
<activesubstancename>MACROGOL</activesubstancename>
</activesubstance>
</drug>
<drug>
<drugcharacterization>2</drugcharacterization>
<medicinalproduct>MORPHINE</medicinalproduct>
<activesubstance>
<activesubstancename>MORPHINE</activesubstancename>
</activesubstance>
</drug>
<drug>
<drugcharacterization>2</drugcharacterization>
<medicinalproduct>IBUPROFEN</medicinalproduct>
<drugdosageform>FILM-COATED TABLET</drugdosageform>
<activesubstance>
<activesubstancename>IBUPROFEN</activesubstancename>
</activesubstance>
</drug>
<drug>
<drugcharacterization>2</drugcharacterization>
<medicinalproduct>DOLCONTIN</medicinalproduct>
<drugdosageform>PROLONGED-RELEASE TABLET</drugdosageform>
<activesubstance>
<activesubstancename>MORPHINE SULFATE</activesubstancename>
</activesubstance>
</drug>
<drug>
<drugcharacterization>2</drugcharacterization>
<medicinalproduct>ALVEDON FORTE</medicinalproduct>
<activesubstance>
<activesubstancename>PARACETAMOL</activesubstancename>
</activesubstance>
</drug>
<drug>
<drugcharacterization>2</drugcharacterization>
<medicinalproduct>CANODERM</medicinalproduct>
<activesubstance>
<activesubstancename>UREA</activesubstancename>
</activesubstance>
</drug>
<drug>
<drugcharacterization>2</drugcharacterization>
<medicinalproduct>SODIUM PICOSULFATE</medicinalproduct>
<drugdosagetext>strength: 7.5 mg/ml</drugdosagetext>
<drugdosageform>ORAL DROPS, SOLUTION</drugdosageform>
<activesubstance>
<activesubstancename>SODIUM PICOSULFATE</activesubstancename>
</activesubstance>
</drug>
<summary>
<narrativeincludeclinical>This serious unsolicited case from Sweden (Local reference number: SE2013023) was received on 16-Jan-2013 from Swedish Health Authority (ref: 124457) via a pharmacist and concerns a 63 year old male patient who experienced hypocalcaemia, paresthesia and muscle cramps whilst receiving cabazitaxel (Jevtana) for prostate cancer.

On 17-Aug-2012, the patient commenced therapy with cabazitaxel (dosage regimen, batch/lot number and expiration date: unspecified). It was reported that 4 regimens had been given and the last together with zoledronic acid. Last dose of cabazitaxel was received on 22-Oct-2012. It was reported that 1 week after the fourth treatment on 29-Oct-2012, the patient was admitted to hospital for cramps in legs, ongoing for 14 days. It was reported that the cramps came &#xc2bf;after sitting for a long time together with small pricking&#xc2bf; (paresthesia). On the same day hypocalcaemia was noted (S-Ca 0.97, reference 2.15-2.50 mmol/L).  No information was provided concerning corrective conduct.

The therapy with cabazitaxel was discontinued. Outcome for the events of hypocalcaemia, paresthesia and muscle cramps was reported as recovering.

The patient was taking zoledronic acid (Zometa), omeprazole, macrogol (Forlax), morphine (nos), ibuprofen (Brufen), morphine sulfate (Dolcontin), paracetamol (Alvedon Forte), urea (Canoderm) and sodium picosulfate (Cilaxoral) concomitantly. No other relevant medical history, concurrent condition and past medications were reported.

The relationship between the events; hypocalcaemia, paresthesia and muscle cramps and cabazitaxel was reported as possible.

No further information was available from Swedish Heath Authority.</narrativeincludeclinical>
<sendercomment>Sanofi-Aventis company comment dated 18 Jan 13: Although the role of cabazitaxel cannot be denied for the events of hypocalcemia and paraesthesia however its role cannot be judged in isolation as other drug are also given concomitantly, the role of which cannot be underestimated.</sendercomment>
</summary>
</patient>
</safetyreport>
</ichicsr>
